Latham & Watkins Advises on Geron Corporation’s US$150 Million Underwritten Offering

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of US$3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock at a price of US$2.999 per pre-funded warrant. The gross proceeds from the offering, before deducting the underwriting discount and other estimated offering expenses, were approximately US$150 million. The offering included participation from RA Capital Management, Fairmount, OrbiMed, Farallon Capital Management, Adage Capital Partners, L.P., Boxer Capital, Vivo Capital, Deep Track Capital, and multiple large investment management firms, in addition to other new and existing investors.

Latham & Watkins LLP represented the underwriters in the offering, with a capital markets team led by partners Shayne Kennedy and Ross McAloon, with associates Gregory Van Buiten, Danny Del Giorno, and Rose Kenyon.